Alcon stock gains focus after Systane study meets endpoint

Alcon reported on October 2, 2026, that SYSTANE PRO Preservative-Free delivered clinically comparable dry-eye symptom relief to MIEBO, or perfluorohexyloctane ophthalmic solution. The company said the product met the study's primary non-inferiority endpoint at two weeks and one month, according to its media release.

The investigator-initiated trial enrolled 256 patients with moderate-to-severe dry-eye symptoms. It was prospective, randomized, double-masked and multicenter, with participants receiving either SYSTANE PRO PF or perfluorohexyloctane four times daily in both eyes.

Study measures symptom relief

Researchers assessed symptoms using the Ocular Surface Disease Index at baseline, two weeks and one month. Alcon said the prespecified non-inferiority margin was 7.3 OSDI units. The between-group difference was minus 2.7 at two weeks and minus 3.0 at one month, with p-values of 0.004 and 0.01, respectively.

Both treatment groups achieved statistically significant and clinically meaningful reductions in OSDI symptoms at two weeks, with the improvement sustained through one month. The results were presented at the American Academy of Optometry 2026 Annual Meeting in Anaheim, held from September 30 through October 3.

Commercial relevance remains ahead

SYSTANE PRO PF is sold over the counter in the United States, Canada and other markets, while MIEBO is available by prescription in the United States. Alcon said the findings add to the evidence supporting SYSTANE PRO PF and reinforce the breadth of its dry-eye portfolio.

For investors, the study provides a clinical data point for a consumer and eye-care product line, but the release does not quantify a sales contribution or change the company's financial outlook. The commercial significance will depend on adoption, pricing and the product's position against prescription and non-prescription alternatives.

Alcon stock traded at 64.21 euros on Lang & Schwarz at 10:11 a.m. CEST on Friday, October 30, 2026. Investors can follow the real-time quote of Alcon stock.

Broader market sentiment can be followed in the SMI market overview.

Alcon's next scheduled results are due on November 10, 2026, according to the company's investor-relations information. Further product adoption data and management commentary will be important for assessing whether the clinical evidence translates into stronger growth. More news and analyses on Alcon stock.